Psoriasin (S100A7) expression and invasive breast cancer
about
Expression analysis of the mouse S100A7/psoriasin gene in skin inflammation and mammary tumorigenesisRanBPM interacts with psoriasin in vitro and their expression correlates with specific clinical features in vivo in breast cancer.S100A7 and the progression of breast cancerExpression patterns of S100A7 (psoriasin) and S100A9 (calgranulin-B) in keratinocyte differentiationChemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathwaysStructural characterization of S100A15 reveals a novel zinc coordination site among S100 proteins and altered surface chemistry with functional implications for receptor bindingHighly homologous hS100A15 and hS100A7 proteins are distinctly expressed in normal breast tissue and breast cancerPsoriasin (S100A7) expression is altered during skin tumorigenesisS100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breastS100A7 (Psoriasin), highly expressed in ductal carcinoma in situ (DCIS), is regulated by IFN-gamma in mammary epithelial cells.S100A7-downregulation inhibits epidermal growth factor-induced signaling in breast cancer cells and blocks osteoclast formation.Loss of ICAM-1 signaling induces psoriasin (S100A7) and MUC1 in mammary epithelial cells.Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancerNuclear S100A7 is associated with poor prognosis in head and neck cancer.Molecular and cellular impact of Psoriasin (S100A7) on the healing of human wounds.Differential role of psoriasin (S100A7) in estrogen receptor α positive and negative breast cancer cells occur through actin remodelingOverexpression of cyclooxygenase-2 in noncancerous liver tissue increases the postoperative recurrence of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis.ERCC1 single nucleotide polymorphism C8092A, but not its expression is associated with survival of esophageal squamous cell carcinoma patients from Fujian province, China.S100 proteins and their influence on pro-survival pathways in cancer.Distinct innate immune gene expression profiles in non-melanoma skin cancer of immunocompetent and immunosuppressed patientsRAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironmentPost-operative recurrent trachomatous trichiasis is associated with increased conjunctival expression of S100A7 (psoriasin).The expression of Psoriasin (S100A7) and CD24 is linked and related to the differentiation of mammary epithelial cells.Knockdown of S100A7 reduces lung squamous cell carcinoma cell growth in vitro and in vivo.Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours.miR-29b defines the pro-/anti-proliferative effects of S100A7 in breast cancer.Psoriasin (S100A7) is a novel biomarker for lung squamous cell carcinoma in humans.S100 proteins in cancer.Tumor-suppressive effects of psoriasin (S100A7) are mediated through the β-catenin/T cell factor 4 protein pathway in estrogen receptor-positive breast cancer cells.The Characteristics and Function of S100A7 Induction in Squamous Cell Carcinoma: Heterogeneity, Promotion of Cell Proliferation and Suppression of DifferentiationExtra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumor behavior and tumor cell proliferation.Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximabExpression of small breast epithelial mucin (SBEM) protein in tissue microarrays (TMAs) of primary invasive breast cancersRelationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancerS100A7 enhances invasion of human breast cancer MDA-MB-468 cells through activation of nuclear factor-κB signalingThe molecular journey from ductal carcinoma in situ to invasive breast cancer.Calcium-sensing receptor in cancer: good cop or bad cop?A multidisciplinary approach to study a couple of monozygotic twins discordant for the chronic fatigue syndrome: a focus on potential salivary biomarkers.Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma.
P2860
Q21261220-823DE917-B3E4-4D69-89DD-0F773D934616Q21261243-8926D1B3-5915-4DC1-B4AE-E3FE3AD66110Q22000741-F198E211-6073-4B04-8507-6857D43B5C20Q24297169-E4741531-0D90-474A-9DA4-C9CA2F312400Q24310573-D42B437F-6E05-4441-AB36-088E7360F488Q24598566-10E8E9F9-C846-4B14-8BC8-59A5672B3BE6Q24607017-69B3F9D3-A6B7-41DB-9973-AA4D3EA082ABQ24646504-60BA6D56-86C8-4B18-90A0-E2EF556487E1Q24805365-7BECCFB0-D9C8-4FBD-B546-662BDD8D422CQ24805971-92F50265-85EA-4C29-A245-8B4D1756A9DCQ33305131-9B8ED3CD-1BB1-4F96-BD9E-CF01B3F577BDQ33322536-72FE3C81-3452-4EF3-949A-391E71C64573Q33539246-A6A7056B-1F35-4A92-BABD-ED47D7536F14Q33589802-D69AF294-6E4D-4A22-B16D-F64F741440B2Q33651153-624C39D0-D386-4645-971A-4F5612B721E5Q33724031-5AF03EC8-2EBA-4500-948E-D6CFA95FDD75Q33804642-EEE9A049-D7C3-40C6-882D-0C6DF93DC54AQ34053320-490E1B87-FD3E-448E-93BE-BA3D9CA24E74Q34142322-C3EE0337-98B1-4D6D-9821-8FBC1B40528FQ34337425-6F92575D-E993-486B-96A3-F745DE63CA2DQ34342371-838BE691-D86D-493F-B52F-8B4BBC3AE8DCQ34457327-44DC19A2-84E0-4CA7-900B-92682041B1BEQ34535324-ABC8D9CC-E5B1-47DF-AB1E-23C6FE1AB2B2Q34541694-0A156585-9C6E-4809-9A00-05ED7C7F6346Q34732996-9ECF464A-DEE8-45E2-BF03-5C6E6FD64236Q34786179-0935A013-1941-4D76-BD13-C04464884211Q35041332-C6F82E6E-19EA-4F23-AF4E-0AFF5EECB8EEQ35150612-8A4D28D8-0527-477D-A8F3-B6BEB249B6C6Q35206368-612D92AC-5FCB-42BF-988B-4817E09366BBQ35639956-179D43F7-1ABE-49B3-A06E-D13116437CFAQ35656741-C1FFF5D9-AF7A-42D4-B2B7-D247A3816584Q35791891-0535E9B9-69F8-4815-8F72-1D48992F6F74Q36207072-C46D4E10-966F-4BE1-88DD-26A3F0C5E021Q36477512-1B78F3D5-0449-4973-B36B-0B46C9E85631Q36646462-865BB4D8-3ACC-422D-A6C9-3CDE65518A8FQ36798341-A3C512F9-9E80-4385-8248-EB3FE7645A64Q37126345-02B9649D-19DE-4411-B5E3-81EF7B204C95Q37326557-2E2B75B5-91AC-4B0E-9236-BF675C9E8D6FQ37363077-563966DF-1AD6-48E7-886C-C4E9336FA30AQ37495292-B1BD7104-1143-4E30-9233-6A99F8F0A609
P2860
Psoriasin (S100A7) expression and invasive breast cancer
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Psoriasin (S100A7) expression and invasive breast cancer
@ast
Psoriasin (S100A7) expression and invasive breast cancer
@en
Psoriasin (S100A7) expression and invasive breast cancer
@en-gb
Psoriasin (S100A7) expression and invasive breast cancer
@nl
type
label
Psoriasin (S100A7) expression and invasive breast cancer
@ast
Psoriasin (S100A7) expression and invasive breast cancer
@en
Psoriasin (S100A7) expression and invasive breast cancer
@en-gb
Psoriasin (S100A7) expression and invasive breast cancer
@nl
prefLabel
Psoriasin (S100A7) expression and invasive breast cancer
@ast
Psoriasin (S100A7) expression and invasive breast cancer
@en
Psoriasin (S100A7) expression and invasive breast cancer
@en-gb
Psoriasin (S100A7) expression and invasive breast cancer
@nl
P2093
P2860
P1476
Psoriasin (S100A7) expression and invasive breast cancer
@en
P2093
L C Murphy
P H Watson
S Al-Haddad
T Hiller-Hitchcock
P2860
P304
P356
10.1016/S0002-9440(10)65524-1
P407
P577
1999-12-01T00:00:00Z